Skip to content

Law firm partners with UTEST program to offer legal advice to early-stage startups

TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST).

This partnership was covered in TechVibes, Law Times and the Financial Post‘s Legal Post blog.

Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.
Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.

UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 in funding, with opportunities for follow-on funding from MaRS Innovation.

In 2014, UTEST was named one of Canada’s most promising start-up accelerators in an online series by BetaKit, a digital publication that covers Canadian technology.

“We are thrilled to partner with A&B and leverage their legal expertise for our startups and emerging companies,” said Kurtis Scissions, who co-directs UTEST with MI’s Mike Betts. “To date, 17 companies, including Granata Decision Systems, Whirlscape, Crowdmark, eQOL and TrendMD, have successfully graduated from our program. We look forward to adding A&B’s Startups Team of lawyers to our mentorship group for the UTEST program, beginning in 2015.”

Continue Reading

MaRS Innovation collaborating with Johnson & Johnson Innovation and Janssen to advance Cardiac, Diabetes and Depression technologies

mi_logoTORONTO, Jan. 12, 2015  — MaRS Innovation, the commercialization agent for Ontario’s 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively.

This announcement was covered in Lab Product News.

“These three projects reflect the quality of innovation present in Toronto’s research community for our industry partners, and Toronto’s progress in addressing healthcare issues of international concern,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Johnson & Johnson Innovation is a long-term strategic partner of MaRS Innovation and of our members; our collaboration reflects the benefits to accessing our members’ deal flow through MaRS Innovation. Through these deals and other scientific exchanges, we see increased interest in Toronto’s innovation and entrepreneurship community.”

The projects’ principal investigators are researchers from the University Health Network (UHN), the Centre for Addiction and Mental Health (CAMH) and the University of Toronto. This announcement follows Johnson & Johnson Innovation’s December 2013 commitment to collaborate on early-stage drug development projects.

Continue Reading

WaveCheck co-directers talk crowdfunding commercialization research on CBC’s “The World This Weekend”

waveMaRS Innovation staff and WaveCheck Campaign Co-directors Dr. Fazila Seker and Elizabeth Monier-Williams spoke with the CBC’s Colleen Ross about the process of crowdfunding WaveCheck’s partner-based clinical studies on “The World This Weekend.”

The radio segment, called “Crowdfunding Science,” aired on January 25, 2014 and discussed the lack of funding researchers have access to for commercialization, making it harder to advance research that could be helping people in a variety of industries.

To listen to the full interview, click here.

WaveCheck’s crowdfunding campaign is an example of how MaRS Innovation gets creative when traditional funding channels take too long or run dry, speeding up the commercialization process.

Continue Reading

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

The commercialization process: Moving transformational ideas from the lab bench to the street
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the market.

Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.

Read the original release via The National Post or in French. MaRS Innovation’s November 25 announcement about the partnership is also available.

This story was covered by GEN: Genetic Engineering Biotechnology News.

Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.

Continue Reading

ChipCare, UTEST and MaRS Innovation profiled in Nature journal article on commercialization programs in Canada

Canadian commercialization and entrepreneurial programs helping scientists and researchers bring their products to market are the focus of a recent article in Nature Journal and on nature.com.

Posted online on October 2, 2013, the article explains how the Centres of Excellence in Commercialization and Research (CECR) programme, and specifically MaRS Innovation, develop research and put it into practice:

MaRS Innovation's commercialization process
MaRS Innovation’s commercialization process: Bridging the gap between brilliant research and successful start-up companies or licensable technologies.

“MARS Innovation and its sister organization MARS Discovery District are not-for-profit organizations that are tightly integrated in Canadian research commercialization. They are based in a heritage building that once belonged to the Toronto University Hospital, in the heart of the city’s ‘discovery district’ — the inner-city conglomeration of universities, institutes and hospitals which has a reputation as a research hotbed. “Here, all the different actors in the commercialization sphere come together in one space,” says Ilse Treurnicht, CEO of MARS Discovery District.

Continue Reading

VitalHub joins Box’s new ecosystem of electronic record healthcare applications

VitalHub Corp Logo: Patient information made easyVitalHub is building on its success in redefining how doctors access patient data by partnering with Box, which announced 13 new partnerships with companies, including VitalHub.

Together, their technology will work across web and mobile devices to help healthcare organizations work with, share and collaborate using information.

Invented at Toronto’s Mount Sinai Hospital in the IT Department, VitalHub was created to effectively manage patient data through a platform allowing clinicians to rapidly access comprehensive, relevant patient information gathered from multiple disparate clinical information systems.

The VitalHub Server platform sits on top of whatever clinical enterprise systems the hospital, community physician practice or healthcare organization already has in place.

Continue Reading
Back To Top